Lpl Financial LLC Immunovant, Inc. Transaction History

Lpl Financial LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 07, 2024	BUY	$25.1 - $31.61 $13,428 - $16,911	535 Added 6.44%	8,848 $233,000
Q1 2024 May 10, 2024	SELL	$30.27 - $43.79 $53,789 - $77,814	-1,777 Reduced 17.61%	8,313 $268,000
Q4 2023 Feb 14, 2024	BUY	$31.31 - $44.19 $3,005 - $4,242	96 Added 0.96%	10,090 $425,000
Q3 2023 Nov 13, 2023	BUY	$18.55 - $39.96 $185,388 - $399,360	9,994 New	9,994 $383,000

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Lpl Financial LLC, based on Form 13F filings with the SEC.

Stay updated on Lpl Financial LLC with notifications on news.